Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB3 | P54753 | 2/20 | 0.36 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 3/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 12/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | CSK | P41240 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25296904 | 0.87 | KDM4E (0.35) | EPHB3EIF4A3PDE2AROCK2LCK | |
| SCHEMBL25252411 | 0.86 | ROCK2 (0.40) | ROCK2 | |
| SCHEMBL25253242 | 0.83 | EPHB3 (0.40) | EPHB3PDE2AROCK2LCKCSK | |
| SCHEMBL25261817 | 0.75 | SMPD3 (0.31) | — | |
| SCHEMBL31546959 | 0.73 | PLA2G4B (0.43) | PDE2A | |
| SCHEMBL17437904 | 0.72 | PRKAB2 (0.40) | ROCK2 | |
| SCHEMBL25252185 | 0.71 | CDK2 (0.36) | HTR2A | |
| SCHEMBL17437950 | 0.71 | ROCK2 (0.47) | EPHB3PDE2AROCK2HTR2AHTR2C | |
| SCHEMBL17324758 | 0.71 | ROCK2 (0.40) | EPHB3PDE2AROCK2LCKCSK | |
| SCHEMBL23888941 | 0.70 | NR1H4 (0.44) | PDE2AROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219979-A1 | PYRAZOLO[1,5-a]PYRIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | SHENZHEN ZHONGGE BIOLOGICAL TECHNOLOGY CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219979-A1 | PYRAZOLO[1,5-a]PYRIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | RET, GRK4, RIN1 | EPHB3 4254/4885EIF4A3 3430/4885PDE2A 1614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.